title: Topical Skin Cancer Therapy Using Doxorubicin-Loaded Cationic Lipid Nanoparticles and lontophoresis.
abstract: The topical administration of chemotherapeutics is a promising approach for the treatment of skin cancer; however, different pharmaceutical strategies are required to allow large amounts of drug to penetrate tumors. This work examined the potential of the anodic iontophoresis of doxorubicin-loaded cationic solid lipid nanoparticles (DOX-SLN) to increase the distribution and tumor penetration of DOX. A double-labeled cationic DOX-SLN composed of the lipids stearic acid and monoolein and a new BODIPY dye was prepared and characterized. The skin distribution and penetration of DOX were evaluated in vitro using confocal microscopy and vertical diffusion cells, respectively. The antitumor potential was evaluated in vivo through the anodic iontophoresis of DOX-SLN in squamous cell carcinoma induced in nude BALB/c mice. The encapsulation of DOX drastically altered the DOX partition coefficient and increased the distribution of DOX in the lipid matrix of the stratum corneum (SC). The association with iontophoresis created high-concentration drug reservoir zones in the follicles of the skin. Although the iontophoresis of a DOX solution increased the penetration of DOX in the viable epidermis by approximately 4-fold, the iontophoresis of cationic DOX-SLN increased the DOX penetration by approximately 50-fold. In vivo, the DOX-SLN iontophoretic treatment was effective in inhibiting tumor cell survival and tumor growth and was accompanied by an increase in keratinization and consequent cell death. These results indicate a strong and synergic effect of iontophoresis with DOX-SLN and provide a potential strategy for the treatment of skin cancer.
authors.forename: Lucas A
authors.initials: LA
authors.lastname: Huber
authors.forename: Tatiana A
authors.initials: TA
authors.lastname: Pereira
authors.forename: Danielle N
authors.initials: DN
authors.lastname: Ramos
authors.forename: Lucas C D
authors.initials: LC
authors.lastname: Rezende
authors.forename: Flávio S
authors.initials: FS
authors.lastname: Emery
authors.forename: Lays Martin
authors.initials: LM
authors.lastname: Sobral
authors.forename: Andréia Machado
authors.initials: AM
authors.lastname: Leopoldino
authors.forename: Renata F V
authors.initials: RF
authors.lastname: Lopez
mesh_terms: D000287:Administration, Topical; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000737:chemistry* / Q000493:pharmacokinetics / Q000627:therapeutic use; D004317:Doxorubicin / Q000008:administration & dosage / Q000737:chemistry* / Q000493:pharmacokinetics / Q000627:therapeutic use; D005260:Female; D007478:Iontophoresis; D008055:Lipids / Q000008:administration & dosage / Q000737:chemistry* / Q000493:pharmacokinetics; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D053758:Nanoparticles / Q000008:administration & dosage / Q000737:chemistry*; D012867:Skin / Q000378:metabolism*; D012869:Skin Absorption; D012878:Skin Neoplasms / Q000188:drug therapy*; D013552:Swine; D023041:Xenograft Model Antitumor Assays
chemical_list: D000970:Antineoplastic Agents; D008055:Lipids; D004317:Doxorubicin